StageZero Life Sciences Investor Relations Material

StageZero Life Sciences Ltd. specializes in providing molecular diagnostic solutions, leveraging a telehealth program that employs advanced diagnostics for the early detection of cancer and chronic diseases. The company is known for developing blood-based biomarker tests, particularly for identifying colorectal cancer. A key innovation from StageZero is its Sentinel Principle technology, which is instrumental in early disease diagnosis, staging, response identification, and treatment monitoring. Additionally, StageZero offers Aristotle, an mRNA-based test capable of detecting multiple cancers from a single blood sample. StageZero Life Sciences is headquartered in Richmond Hill, Ontario, and its shares are listed on the Toronto Stock Exchange.